FMP

FMP

Enter

ALPHA.PA - Pharnext SA

Analysis of Pharnext SA(ALPHA.PA), Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common ne

photo-url-https://financialmodelingprep.com/image-stock/ALPHA.PA.png

Pharnext SA

ALPHA.PA

EURONEXT

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

0.0018 EUR

-0.0008 (-44.44%)

page loading card

Upgrades & Downgrades

We are unable to load this data!

fmp-logo

Price PriceTargets

We are unable to load the data!

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep